Effect of eplerenone on parathyroid hormone levels in patients with primary hyperparathyroidism: a randomized, double-blind, placebo-controlled trial
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Increasing evidence suggests the bidirectional interplay between parathyroid hormone and aldosterone as an important mechanism behind the increased risk of cardiovascular damage and bone disease observed in primary hyperparathyroidism. Our primary object is to assess the efficacy of the mineralocorticoid receptor-blocker eplerenone to reduce parathyroid hormone secretion in patients with parathyroid hormone excess. METHODS/DESIGN: Overall, 110 adult male and female patients with primary hyperparathyroidism will be randomly assigned to eplerenone (25 mg once daily for 4 weeks and 4 weeks with 50 mg once daily after dose titration] or placebo, over eight weeks. Each participant will undergo detailed clinical assessment, including anthropometric evaluation, 24-h ambulatory arterial blood pressure monitoring, echocardiography, kidney function and detailed laboratory determination of biomarkers of bone metabolism and cardiovascular disease.The study comprises the following exploratory endpoints: mean change from baseline to week eight in (1) parathyroid hormone(1-84) as the primary endpoint and (2) 24-h systolic and diastolic ambulatory blood pressure levels, NT-pro-BNP, biomarkers of bone metabolism, 24-h urinary protein/albumin excretion and echocardiographic parameters reflecting systolic and diastolic function as well as cardiac dimensions, as secondary endpoints. DISCUSSION: In view of the reciprocal interaction between aldosterone and parathyroid hormone and the potentially ensuing target organ damage, the EPATH trial is designed to determine whether eplerenone, compared to placebo, will effectively impact on parathyroid hormone secretion and improve cardiovascular, renal and bone health in patients with primary hyperparathyroidism. TRIAL REGISTRATION: ISRCTN33941607.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Plasma Parathyroid Hormone and the Risk of Cardiovascular Mortality in the Community
Hagström, E., Hellman, P., Larsson, T. E., Ingelsson, E., Berglund, L., Sundström, J., Melhus, H., Held, C., Lind, L., Michaëlsson, K., et al. (2009) · Circulation · doi:10.1161/circulationaha.108.808733 · Cited by 416
Amrein, K., Amrein, S., Drexler, C., Dimai, H. P., Dobnig, H., Pfeifer, K., Tomaschitz, A., Pieber, T. R., & Fahrleitner-Pammer, A. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-2152 · Cited by 277
Self-citationArterial Stiffness in Mild Primary Hyperparathyroidism
Rubin, M. R., Maurer, M. S., McMahon, D. J., Bilezikian, J. P., & Silverberg, S. J. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-1400 · Cited by 145 · cited 1×
“hypertension as well as increased arterial stiffness [37-40].”
BackgroundPTH and PTH-related peptide enhance steroid secretion from human adrenocortical cells
Mazzocchi, G., Aragona, F., Malendowicz, L. K., & Nussdorfer, G. G. (2001) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.2001.280.2.e209 · Cited by 123
Pilz, S., Kienreich, K., Drechsler, C., Ritz, E., Fahrleitner-Pammer, A., Gaksch, M., Meinitzer, A., März, W., Pieber, T. R., & Tomaschitz, A. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-2183 · Cited by 118
Self-citationPrimary Hyperparathyroidism With Concurrent Primary Aldosteronism
Maniero, C., Fassina, A., Guzzardo, V., Lenzini, L., Amadori, G., Pelizzo, M. R., Gomez-Sanchez, C., & Rossi, G. P. (2011) · Hypertension · doi:10.1161/hypertensionaha.111.173948 · Cited by 94 · cited 1×
“and in normal parathyroid gland tissue [31].”
Brunaud, L., Germain, A., Zarnegar, R., Rancier, M., Alrasheedi, S., Caillard, C., Ayav, A., Weryha, G., Mirallie, E., & Bresler, L. (2009) · Surgery · doi:10.1016/j.surg.2009.09.041 · Cited by 83 · cited 1×
“nificantly decreased aldosterone and BP levels [30].”
Fracture Risk in Men With Congestive Heart Failure
Carbone, L. D., Cross, J. D., Raza, S. H., Bush, A. J., Sepanski, R. J., Dhawan, S., Khan, B. Q., Gupta, M., Ahmad, K., Khouzam, R. N., et al. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.03.039 · Cited by 79
Kovacs, L., Goth, M., Szabolcs, I., Dohan, O., Ferencz, A., & Szilagyi, G. (1998) · European Journal of Endocrinology · doi:10.1530/eje.0.1380543 · Cited by 66 · cited 1×
“[28,29].”
Response of adrenal cells to parathyroid hormone stimulation
Rosenberg, J., Pines, M., & Hurwitz, S. (1987) · Journal of Endocrinology · doi:10.1677/joe.0.1120431 · Cited by 53 · cited 2×
“and others found that PTH and PTH-related protein increase in human adrenals aldosterone production by binding to the PTH/PTH-RP receptor [11,12].”
Background
Cited by
Brown, J. M., Williams, J. S., Luther, J. M., Garg, R., Garza, A. E., Pojoga, L. H., Ruan, D. T., Williams, G. H., Adler, G. K., & Vaidya, A. (2014) · Hypertension · doi:10.1161/hypertensionaha.113.01910 · Cited by 88
Interactions between adrenal-regulatory and calcium-regulatory hormones in human health
Brown, J. M., & Vaidya, A. (2014) · Current Opinion in Endocrinology, Diabetes & Obesity · doi:10.1097/med.0000000000000062 · Cited by 39
Interrelated aldosterone and parathyroid hormone mutually modify cardiovascular mortality risk
Tomaschitz, A., Pilz, S., Rus-Machan, J., Meinitzer, A., Brandenburg, V. M., Scharnagl, H., Kapl, M., Grammer, T., Ritz, E., Horina, J. H., et al. (2015) · International Journal of Cardiology · doi:10.1016/j.ijcard.2015.03.062 · Cited by 27
Self-citationTomaschitz, A., Verheyen, N., Meinitzer, A., Pieske, B., Belyavskiy, E., Brussee, H., Haas, J., März, W., Pieske-Kraigher, E., Verheyen, S., et al. (2016) · Journal of Hypertension · doi:10.1097/hjh.0000000000000927 · Cited by 24
Self-citationVerheyen, N., Fahrleitner-Pammer, A., Pieske, B., Meinitzer, A., Belyavskiy, E., Wetzel, J., Gaksch, M., Grübler, M. R., Catena, C., Sechi, L. A., et al. (2016) · Journal of Hypertension · doi:10.1097/hjh.0000000000001004 · Cited by 24
Self-citation
Metadata
- Authors
- Tomaschitz, A., Fahrleitner-Pammer, A., Pieske, B., Verheyen, N., Amrein, K., Ritz, E., Kienreich, K., Horina, J. H., Schmidt, A., Kraigher-Krainer, E., Colantonio, C., Meinitzer, A., & Pilz, S.
- Venue
- BMC Endocrine Disorders
- Published
- 2012-09-13
- Volume
- 12
- Issue
- 1
- Pages
- 19-19
- ISSN
- 1472-6823 (ISSN-L)
- OpenAlex
- W2020817208
- Cited by
- 26
- References
- 11
- FWCI
- 3.45
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effect of eplerenone on parathyroid hormone levels in patients with primary hyperparathyroidism: a randomized, double-blind, placebo-controlled trial. https://app.cochat.ai/papers/10.1186/1472-6823-12-19
- The paper
- Tomaschitz, A., Fahrleitner-Pammer, A., Pieske, B., Verheyen, N., Amrein, K., Ritz, E., Kienreich, K., Horina, J. H., Schmidt, A., Kraigher-Krainer, E., Colantonio, C., Meinitzer, A., & Pilz, S. (2012). Effect of eplerenone on parathyroid hormone levels in patients with primary hyperparathyroidism: a randomized, double-blind, placebo-controlled trial. BMC Endocrine Disorders. https://doi.org/10.1186/1472-6823-12-19
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.